Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Emergent BioSolutions Inc.NYSE: EBS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of $67.6M fell 42.0% year over year, behind the -14.5% change in trailing-twelve-month gross profit. Sequentially, it rose 45.1% from the prior quarter. Over 3 fiscal years it compounded at -9.5% a year.

Context

  • Gross profit amounted to 47.2% of revenue in FY2025, up 11.2 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -42.0% toward the trailing-twelve-month pace of -14.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$67.6M+45.1% QoQ
Last fiscal yearDec 2025
$350.6M-6.6% YoY
LTMMar 2026
$300.8M-14.5% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.0%——
1 year-6.6%——
3-year CAGR-9.5%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
350.6M USD
Year-over-year change
-6.6%
4-year CAGR
-18.5%

Gross Profit vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -14.5% is the 6th highest of 8, against a peer median of +3.3%.
  • Gross profit amounts to 44.4% of revenue for EBS, versus a peer median of 65.0%.
EBS Competitors
Gross Profit for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$361.62M USD+3.9%+7.2%70.4%
EBSEmergent BioSolutions Inc.LTM Mar 2026$300.8M USD-14.5%-9.5%44.4%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$279.95M USD+53.8%+32.3%93.4%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$271.85M USD+60.4%+78.1%65.0%
SNDLSNDL Inc.LTM Mar 2026CA$254.82M CAD+3.3%+22.6%27.2%
SIGASIGA Technologies, Inc.LTM Mar 2026$61.29M USD-33.5%-13.5%65.4%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$31.9M USD-14.0%-1.1%63.5%
PRTAProthena Corporation plcLTM Mar 2026$27.14M USD-80.3%-51.9%46.8%
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$55K USD———
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$306K USD———
Peer median (excluding EBS) —+3.3%+7.2%65.0%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.